SERA PROGNOSTICS, INC. Deferred Federal Income Tax Expense (Benefit)
SERA PROGNOSTICS, INC. (SERA) reported Deferred Federal Income Tax Expense (Benefit) of -$6.79 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-03-18
- SERA PROGNOSTICS, INC. deferred federal income tax expense (benefit) for fiscal 2025 was -$6.79M.
- SERA PROGNOSTICS, INC. deferred federal income tax expense (benefit) for fiscal 2024 was -$8.98M, a 209.82% decline from fiscal 2023.
- SERA PROGNOSTICS, INC. deferred federal income tax expense (benefit) for fiscal 2023 was $8.18M, a 13.00% decline from fiscal 2022.
- SERA PROGNOSTICS, INC. deferred federal income tax expense (benefit) for fiscal 2022 was $9.40M, a 16.78% increase from fiscal 2021.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$6.79M 10-K · filed 2026-03-18 | |
| 2024-12-31 | -$8.98M 10-K · filed 2026-03-18 | $8.98M 10-K · filed 2025-03-19 |
| 2023-12-31 | $8.18M 10-K · filed 2025-03-19 | |
| 2022-12-31 | $9.40M 10-K · filed 2024-03-20 | |
| 2021-12-31 | $8.05M 10-K · filed 2023-03-22 | |
| 2020-12-31 | $3.66M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |